Q3 2024 Earnings Estimate for Pyxis Oncology, Inc. (NASDAQ:PYXS) Issued By William Blair

Pyxis Oncology, Inc. (NASDAQ:PYXS) – Equities research analysts at William Blair upped their Q3 2024 earnings per share (EPS) estimates for Pyxis Oncology in a research note issued on Wednesday, August 14th. William Blair analyst A. Hsieh now expects that the company will earn ($0.32) per share for the quarter, up from their previous estimate of ($0.35). The consensus estimate for Pyxis Oncology’s current full-year earnings is ($1.09) per share. William Blair also issued estimates for Pyxis Oncology’s Q4 2024 earnings at ($0.31) EPS, FY2024 earnings at ($1.00) EPS, Q1 2025 earnings at ($0.32) EPS, Q2 2025 earnings at ($0.32) EPS, Q3 2025 earnings at ($0.32) EPS, Q4 2025 earnings at ($0.32) EPS, FY2025 earnings at ($1.28) EPS and FY2026 earnings at ($1.28) EPS.

Several other equities research analysts also recently weighed in on the company. Stifel Nicolaus assumed coverage on Pyxis Oncology in a report on Thursday, August 8th. They issued a “buy” rating and a $10.00 price target on the stock. Jefferies Financial Group restated a “buy” rating and set a $10.00 price objective on shares of Pyxis Oncology in a report on Tuesday, May 7th. Finally, HC Wainwright restated a “buy” rating and set a $7.00 price objective on shares of Pyxis Oncology in a report on Friday. Eight research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $9.00.

Pyxis Oncology Stock Performance

Shares of NASDAQ PYXS opened at $3.62 on Monday. The business’s 50 day moving average price is $3.40 and its 200-day moving average price is $4.22. Pyxis Oncology has a fifty-two week low of $1.35 and a fifty-two week high of $6.85. The company has a market cap of $213.17 million, a price-to-earnings ratio of -2.66 and a beta of 1.29.

Institutional Trading of Pyxis Oncology

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Fullcircle Wealth LLC bought a new stake in Pyxis Oncology during the 2nd quarter valued at $40,000. SG Americas Securities LLC bought a new stake in Pyxis Oncology during the 1st quarter valued at $59,000. The Manufacturers Life Insurance Company bought a new stake in Pyxis Oncology during the 2nd quarter valued at $65,000. Schulhoff & Co. Inc. boosted its position in Pyxis Oncology by 90.9% during the 2nd quarter. Schulhoff & Co. Inc. now owns 42,000 shares of the company’s stock valued at $139,000 after acquiring an additional 20,000 shares in the last quarter. Finally, American Century Companies Inc. boosted its position in shares of Pyxis Oncology by 56.0% in the 2nd quarter. American Century Companies Inc. now owns 58,252 shares of the company’s stock worth $193,000 after purchasing an additional 20,901 shares in the last quarter. Institutional investors own 39.09% of the company’s stock.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.